CONTACT
+91 80 2808 2808
info@biocon.com
About Us
Overview
Who we are
Our Key Priorities
Board of Directors
Key Management Team
Our Legacy
Fact Sheet
Our Stories
Scientific Publications
Awards & Recognition
Products
Overview
Key Therapeutic Areas
Generics
Biosimilars
Novel Biologics
Branded Formulations
Businesses
Overview
Generics
Executive Leadership Team
API
Generic Formulations
Quality & Compliance
Manufacturing Operations
Research & Development
Regulatory Affairs
Biosimilars
Biocon Biologics
Board of Directors
Executive Leadership Team
Global Portfolio
Wide Global Footprint
Quality & Compliance
Partners
Global Scale Manufacturing
Research & Development
Branded Formulations
Novel Biologics
Biocon and Novels
Novels Pipeline
Research Services
Investors
Overview
Financial Fact Sheet
Financial Information
Annual Reports
Quarterly Reports
Key Figures (Annual & Quarterly)
Earnings Call Recordings
Earnings Call Transcripts
Subsidiary Financials
Investor Presentations
Corporate Governance
Overview
Board of Directors
Board Committees
Our Leadership
Corporate Structure
Company History & Milestones
Governance Documents & Policies
Share Information
Share Graph
Share Series
Share Price Look Up
Investment Calculator
Share Price Alerts
Fragulizer
Dividends
Unclaimed and Unpaid Dividend
IEPF
Shareholder Services
Annual General Meeting
Postal Ballot
Investor Feedback
Investor FAQ
Miscellaneous Communication
Financial Calendar
Stock Exchange Disclosures
Notice of Board Meeting
Investors Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements & Disclosures
Analyst Coverage
Code Of Conduct
Email Subscription Services
Investor Contact
Disclosures under Regulation 46 of LODR
Careers
Overview
Working With Us
Now Hiring
Functions
Our Culture
Diversity And Inclusion
Learning & Development
Awards & Recognition
Benefits
Meet Our Employees
Career FAQ’s
Responsibility
Overview
Biocon Foundation
Social Impact
Partners
Grant-in-Aid
Awards and Recognition
Sustainability
Safer Workplace
An Environment of Change
Environmental Clearance
EHS Certifications
Biocon Academy
News
Overview
Press Releases
Company Statements
Media Stories
Image Gallery
Video Gallery
Events & Calendar
Media Contacts
More+
Contact Us
Blog
For Patients
Biocon in Malaysia
Group Companies
Syngene
Biocon BIologics
Bicara
Biocon Academy
Company Statements 2019
Biocon
/
News – Posts
/
Company Statements
/
Company Statements 2019
U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru
Fri, 20-Sep-2019
Posted by: BIOCON
No Comments
U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged
Sat, 31-Aug-2019
Posted by: BIOCON
No Comments
U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru
Sat, 31-Aug-2019
Posted by: BIOCON
No Comments
Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia
Mon, 08-Jul-2019
Posted by: BIOCON
No Comments
Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification
Fri, 14-Jun-2019
Posted by: BIOCON
No Comments
Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan
Tue, 07-May-2019
Posted by: BIOCON
No Comments
Biocon Facility Completes Pre Approval U.S. FDA Inspection
Wed, 06-Mar-2019
Posted by: BIOCON
No Comments
Biocon Facilities complete Pre Approval U.S. FDA lnspection
Mon, 18-Feb-2019
Posted by: BIOCON
No Comments
